Darolutamide with chemo for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with prostate cancer that has spread to other parts of the body.
- You must be able to walk and take care of yourself (ECOG score 0 or 1).
- Your blood counts and liver/kidney function need to be good enough for treatment.
- You cannot have had certain hormone therapies (like darolutamide, enzalutamide, or abiraterone) or chemotherapy before.
- You have not had radiation therapy in the last 2 weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
This study tests a triple treatment (darolutamide, hormone therapy, and chemotherapy) for men whose prostate cancer has spread and still responds to hormone therapy. The goal is to see if this combination works better than standard care in controlling the cancer and improving outcomes.
This trial tests a new combination treatment for men with advanced prostate cancer that has stopped responding to usual hormone therapy. It compares high-dose testosterone followed by darolutamide to standard care, and may help control the cancer longer.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.